RetinalGenix Technologies has entered into a nationwide agreement with LabCorp to support the rollout of its DNA/RNA/GPS Pharmaco-Genetic Mapping platform, a hybrid diagnostic solution designed to advance early detection of both ocular and systemic diseases. The collaboration enables patients to access genetic screening and high-resolution retinal imaging services through LabCorp locations across the United States.

Patients can anonymously submit samples—blood, saliva, tears, or nasal secretions—which are analyzed using proprietary RetinalGenix algorithms. The platform is designed to uncover correlations between genetic markers and retinal biomarkers, potentially improving early detection of conditions ranging from eye diseases to neurological and cardiovascular disorders. Taimour Langaee, PhD, who oversees the company’s data processing and analysis, noted the potential to uncover new genetic variants that are tied to eye diseases and develop precision medicine-based treatments.

The platform’s methodology is designed to reduce health care costs by offering a lower-cost alternative to expensive diagnostics such as MRIs, CT scans, PET scans, and echocardiograms, said RetinalGenix CEO Dr. Jerry Katzman. The company is also working with regulators to establish CPT codes for reimbursement, which may further improve access and affordability. Patients manage appointments and results through the digital platform, and all data remains anonymous and confidential; results are released only after validated payment.

RetinalGenix reports that it plans to introduce high-resolution retinal imaging as a value-added service at selected sites. This addition is expected to enhance diagnostic accuracy and broaden access to mass screening, including in primary care and general ophthalmic settings. RP